An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-008504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Cesare Di Nitto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Philochem AG, Otelfingen, Switzerland. Hauptthemen laut MEDLINE: Fibronectins, CD8-Positive T-Lymphocytes, Interleukin-7. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Anti-PD-1 antibodies have revolutionized cancer immunotherapy due to their ability to induce long-lasting complete remissions in a proportion of patients. Current research efforts are attempting to identify biomarkers and suitable combination partners to predict or further improve the activity of immune checkpoint inhibitors. Antibody-cytokine fusions are a class of pharmaceuticals that showed the potential to boost the anticancer properties of other immunotherapies. Extradomain A-fibronectin (EDA-FN), which is expressed in most solid and hematological tumors but is virtually undetectable in healthy adult tissues, is an attractive target for the delivery of cytokine at the site of the disease.
Methods
In this work, we describe the generation and characterization of a novel interleukin-7-based fusion protein targeting EDA-FN termed F8(scDb)-IL7. The product consists of the F8 antibody specific to the alternatively spliced EDA of FN in the single-chain diabody (scDb) format fused to human IL-7.
Results
F8(scDb)-IL7 efficiently stimulates human peripheral blood mononuclear cells in vitro. Moreover, the product significantly increases the expression of T Cell Factor 1 (TCF-1) on CD8+T cells compared with an IL2-fusion protein. TCF-1 has emerged as a pivotal transcription factor that influences the durability and potency of immune responses against tumors. In preclinical cancer models, F8(scDb)-IL7 demonstrates potent single-agent activity and eradicates sarcoma lesions when combined with anti-PD-1.
Conclusions
Our results provide the rationale to explore the combination of F8(scDb)-IL7 with anti-PD-1 antibodies for the treatment of patients with cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Philochem AG, Otelfingen, Switzerland.
- Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
- Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
- University of Zurich, Zurich, Switzerland.
- Philogen SpA, Siena, Italy.
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
ORCID-Profile: Christian Pellegrino, Tobias Weiss, Roberto De Luca
Zitieren
APA
Di Nitto, C., Ravazza, D., Gilardoni, E., Look, T., Sun, M., Prodi, E., Moisoiu, V., Pellegrino, C., Manz, M. G., Puca, E., Weller, M., Weiss, T., Neri, D., & De Luca, R. (2024). An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008504
Vancouver
Di Nitto C, Ravazza D, Gilardoni E, Look T, Sun M, Prodi E, et al. An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008504
BibTeX
@article{DiNitto2024,
author = {Di Nitto, Cesare and Ravazza, Domenico and Gilardoni, Ettore and Look, Thomas and Sun, Miaomiao and Prodi, Eleonora and Moisoiu, Vlad and Pellegrino, Christian and Manz, Markus G and Puca, Emanuele and Weller, Michael and Weiss, Tobias and Neri, Dario and De Luca, Roberto},
title = {An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-008504}
}
EUVIMED